NEW YORK, January 14, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Teva Pharmaceutical Industries Limited (NYSE: TEVA), Novartis AG (NYSE: NVS), Illumina Inc. (NASDAQ: ILMN), Becton, Dickinson and Company (NYSE: BD) and Universal Health Services Inc. (NYSE: UHS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Teva Pharmaceutical Industries Limited Research Report
On January 9, 2014, Teva Pharmaceutical Industries Limited (TEVA) reported that it will conduct a live audio webcast of its presentation at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. According to the Company, Eyal Desheh, TEVA's acting President and CEO will host the aforesaid presentation on Tuesday, January 14, 2014 at 10:30 a.m. PT. The Company informed that interested parties can access a live webcast of the presentation via a link provided on TEVA's website. The Full Research Report on Teva Pharmaceutical Industries Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Novartis AG Research Report
On January 9, 2014, Novartis AG's (Novartis) stock increased 1.38%, ending the day's trading session at $80.81. Over the previous three trading sessions, shares of Novartis increased 2.05%, compared to the Dow Jones Industrial Average Index, which also increased 0.12% during the same period. The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Illumina Inc. Research Report
On January 9, 2014, Illumina Inc. (Illumina) reported that it has signed a multi-year licensing agreement with Quest Diagnostics (Quest), regarding the use of Illumina's next-generation sequencing technology for clinical laboratory testing. The Company informed that under the terms of the agreement, Quest will be granted broad rights to utilize Illumina's sequencing and genotyping technology, along with the MiSeq® platform and related consumables, to develop, validate and offer molecular laboratory-developed tests for several disease states to clinicians in the United States. According to the Company, Quest also has the rights to utilize the Illumina equipment as biomarker test services in clinical trials performed on behalf of its pharmaceutical, biotechnology and other clients. Jay Wohlgemuth, M.D., Senior Vice President, Science and Innovation at Quest, commented, "Quest's science and innovation strategy is focused on accelerating the introduction of clinically meaningful diagnostic solutions that aid the management of the individual patient across a continuum of care, promoting better outcomes. Investing in next-generation sequencing, which is increasingly used in several clinical areas as well as clinical trials, is a key element of our strategy. Illumina is a leader in NGS innovation, and this new broad agreement will give us a greater level of flexibility to build on our record of success in NGS to include several diseases where sequencing-based molecular testing can meaningfully improve clinical care." Nick Naclerio, Illumina's Senior Vice President of Corporate and Venture Development, added, "We are excited to support Quest's further expansion into next-generation sequencing. Quest's advanced development capabilities and vast clinician network will help bring the power of next-generation sequencing to an ever larger range of patients around the U.S." The Full Research Report on Illumina Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Becton, Dickinson and Company Research Report
On January 7, 2014, Becton, Dickinson and Company (BD) reported that it will conduct a live webcast of its Q1 FY 2014 earnings conference call on Tuesday, February 4, 2014, at 8:00 a.m. ET. According to the Company, interested parties can access a webcast of the conference call and the related slides via BD's website. The webcast and slides will be archived and will be available for replay at BD's website until Tuesday, February 11, 2014. The Full Research Report on Becton, Dickinson and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Universal Health Services Inc. Research Report
On January 8, 2014, Universal Health Services Inc. (UHS) reported that its Senior Vice President and CFO, Steve Filton will represent the Company at the JP Morgan 32nd Annual Healthcare Conference in San Francisco, California, on Wednesday, January 15, 2014 at 1:30 p.m. PST. According to the Company, interested parties can access a live audio webcast of the presentation via UHS' website. UHS will also archive a replay of the webcast at its website for 90 days after the completion of the conference call. The Full Research Report on Universal Health Services Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner